Where Does Novartis Go From Here In Oncology? A Conversation With Its Oncology, Gene Therapy Execs
Novartis may be behind other big rivals that already have immuno-oncology therapies on the market but its top R&D scientists Alessandro Riva and Usman Azam say it can leap frog to a front position using its early IO pipeline and targeted cancer drugs.
You may also be interested in...
In back-to-back deals with AstraZeneca and Juno, Celgene has fronted nearly $1.5 billion to become a serious contender in the field of cancer immunotherapy, and is looking to lead in blood cancers.
With PD-1 immunotherapy continuing to make gains in melanoma, will Yervoy and targeted BRAF/MEK combos from Novartis, Roche and Array BioPharma get relegated to second-class status?
Novartis hopes its multi-year deal with Aduro Biotech to develop molecules to unlock dormant immune cells by targeting and activating a central signaling pathway called STING will allow it to make up for lost time and catch “the next wave” in immuno-oncology.